Ted Smith, MD, PhD: Collaboration and Advancements in the Retina Space


R. Theodore Smith MD, PhD, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai discusses new research to reduce the burden of AMD and how imaging can revolutionize the retina space.

At the American Academy of Ophthalmology Annual Meeting 2018, R. Theodore Smith, MD, PhD, sat down with MD Magazine® to discuss some new research to reduce the burden of age-related macular degeneration (AMD) and how retina imaging can revolutionize the space.

Dr. Smith, a professor of ophthalmology at Icahn School of Medicine at Mount Sinai, will be presenting his research on hyperspectral autofluorescence imaging of AMD later this weekend in a presentation at the meeting.

Interview transcript: (modified slightly for readability)

MD Magazine®: What are some areas of research that you are focusing on in the ophthalmology space?

Smith: We’re also looking at the characteristic lesions of age-related macular degeneration that are most strongly associated with systemic vascular disease. Some of our patients also suffer heart disease, they’ve had strokes, and what we’ve found is that those patients have a particular manifestation of macular degeneration of the subretinal deposits. We can detect those on OCT imaging and on all the fluorescent imaging.

So, we’re trying to work with our colleagues in cardiology and neurology to determine who are the most vulnerable patients and what cohorts we should be following most carefully for their systemic diseases and their effect on their eyes.

MD Magazine®: What are some important takeaways for physicians in the retina field?

Smith: I think that in broad terms, for those of us in the retina field, different types of retina imaging offer different types of information. The more that we can learn from imaging, the more we can learn about the disease processes in a very non-invasive way; so, we don’t have to go and get tissues, we don’t have to take biopsies, we can take pictures with different types of cameras and I think that’s the way of the future, to understand and manage those diseases.

Related Videos
A panel of 3 experts on ocular diseases and conditions
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials | Image Credit: HCPLive
Elamipretide in ReCLAIM-2 Trial | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Signs and Symptoms of Connective Tissue Disease
© 2024 MJH Life Sciences

All rights reserved.